Lantern Pharma Seeks FDA Feedback on HARMONIC Trial Protocol Amendments for Lung Cancer Drug
Lantern Pharma has scheduled a Type C meeting with the FDA to discuss proposed changes to its Phase 2 HARMONIC trial for LP-300 in non-small cell lung cancer, focusing on EGFR Exon 21 L858R patients based on promising clinical data.
Lantern Pharma Inc. (NASDAQ: LTRN) has scheduled a Type C meeting with the U.S. Food and Drug Administration for mid-May 2026 to discuss proposed protocol amendments for its Phase 2 HARMONIC trial. The clinical-stage precision oncology company seeks regulatory feedback on modifications to its study evaluating LP-300 in non-small cell lung cancer patients.
The proposed changes include focusing enrollment specifically on patients with EGFR Exon 21 L858R mutations, shifting from a randomized to a single-arm study design, and extending treatment cycles. These amendments are supported by emerging clinical data showing an 8.3-month median progression-free survival and encouraging response rates in this difficult-to-treat population. The HARMONIC trial targets never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment.
Lantern Pharma leverages artificial intelligence, machine learning, and its proprietary RADR platform to transform cancer therapy development. The company's clinical pipeline includes multiple compounds, with LP-300 being a cisplatin/ethacraplatin analog under investigation. The company also operates an AI Center of Excellence in Bengaluru, India, while maintaining its headquarters in Dallas, Texas.
The company has developed Zeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for Lantern Pharma alongside its therapeutic development programs. Additional information about the company is available through its newsroom at https://ibn.fm/LTRN.
This regulatory engagement represents a significant step in optimizing the HARMONIC trial design to potentially accelerate development of LP-300 for a specific genetic subset of lung cancer patients. The proposed amendments reflect data-driven adjustments that could enhance the trial's efficiency and relevance for the targeted patient population with limited treatment options.